Never in my wildest dreams I had imagined what happened last week. I am still contemplating it. I feel truly blessed to achieve this milestone after an incredible journey and unwavering support from family and friends.@KUSM_Wichita #Match2023 #IMG @Inside_TheMatch

So will this finally change practice? #AHA25 #CLOSUREAF

While I am an enthusiastic supporter of AI in clinical medicine, I share many of the concerns voiced in this excellent piece. “We risk entering a perverse loop: machines are supplying the language with which patients relay their suffering, and doctors are using machines to

🎀 New Stroke Risk Tool for Breast Cancer + AF Patients! 🧩 B-S CALED - the first breast-cancer–specific, externally validated stroke-risk score beats CHA₂DS₂-VASc in predicting ischemic stroke/TIA 🧠 📊 Study design: 🏥 UH Seidman Cancer Center – 935 pts (derivation) 🏥 MCG

Our newsletter has the latest news from our campus, from student and staff achievements to the JayDoc Pickleball Tournament 🏓 plus a wickedly successful event for the Sweet Emergency Fund. Take a look: https://t.co/SNTPzByPu7

🚶‍♀️🏃‍♂️ The most powerful cancer prevention tool isn’t in a pill - it’s your daily walk. 30 years of data prove it.” 📊 231,000 adults followed for 3 decades 💪 17 MET-hours/week (~4 h brisk walk or 2 h jog) = 🔻 17% ↓ digestive cancer risk 🔻 28% ↓ cancer deaths But here’s the

For those looking for a nice summary on AI in therapeutic decision-making in oncology, here you go. Whether you are an enthusiastic supporter of AI or somewhat of a Luddite (but willing to learn/adapt) like me, your job is going to change drastically... https://t.co/kwzJGGKjAy

Epoetin: From life-saving to dangerous therapy in dialysis 1989-2005 This is a clinical history of the 5th biologic protein approved by the FDA under the brand name EPOGEN. Use of epoetin had an immediately life-saving impact on management of anemia in CKD patients. 1/

My first NANETS! 🦓 Thanks to @UGrewalMD. What an amazing day. Glad to meet colleagues and mentors @Jani_Chinmay #NANETs. @KUSM_Wichita

Breaking: And I’m glad. This is an important option we need for patients with myeloma. FDA has approved belantamab in combination with bortezomib and dex (BVd) for relapsed or refractory multiple myeloma in patients who have received at least two prior lines of therapy,

If your diabetes management plan starts with a sliding scale, congratulations — you’ve officially time-travelled back to 1975

First time attending? You belong here 💡 Whether you're brand new to NETs or a seasoned participant, we offer programming and guidance to help you make the most of your time in Austin. #NETs #MedicalCommunity #SymposiumExperience #ProfessionalGrowth #Networking

🚨 ESMO 2025 | LBA15 (AIIMS Delhi) 🧬 Low-dose Pembrolizumab in TNBC Phase II RCT: Pembrolizumab 50 mg q6wk × 3 + NACT vs NACT alone 👉 pCR 53.8% vs 40.5% (Δ 13.3%, p = 0.047) ➡️ Nearly matches KN-522 results at a fraction of the dose and cost. 💊 Grade ≥ 3 AEs: 50% vs 59.5%

The dream team ❤️ Honored to be part of this family ✨

Stop celebrating FOMO. It's a dream and this dream depresses you. Stay in the present and be happy!

💔 Hidden Heart Damage After Childhood Cancer 🏥 PanCareSurFup + ProCardio study (n ≈ 70 K, 7 European nations 🇫🇷🇬🇧🇳🇱🇮🇹🇭🇺🇨🇭🇸🇮) 🔎 What They Found? ❤️ Heart RT ≥ 5 Gy → VHD risk ↑ 4.7× 💥 Heart RT ≥ 30 Gy → risk ↑ > 100× vs no RT! 💊 Anthracyclines ≥ 400 mg/m² → risk

🎶 The Fab 4 of #ESMO25 GU Trials 🎶 ( the Beatles of GU oncology) 👑 Paul – PSMAddition (LBA6) ✨The melodic leader 🎤 ➡️ [¹⁷⁷Lu]Lu-PSMA-617 + ADT + ARPI in PSMA+ mHSPC. 🎶Setting the rhythm for theranostics to move upfront. 🎸 John – ENZUP 1303 ( LBA86) ✨ The bold

🎯 ITT vs TPP - the most misunderstood twins in clinical trials! Both look similar in papers… but they tell completely different stories. Let’s break it down the easy way 👇 1️⃣ ITT - Intention-To-Treat 🧠 “Once randomized, always analyzed.” Even if the patient skipped doses,

🩷 2025 St Gallen Consensus: Redefining Early Breast Cancer, One Decision at a Time 🧬 🧩 Genetics & Risk 🧬 Test if ≤ 50 y, TNBC, strong family hx -not universal 🦋 BRCA / PALB2 → Olaparib 🧫 ATM, CHEK2, BARD1, RAD51 → surveillance 🩺 Surgery & Axilla 🩹 Omit SLNB in

BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

🚫💉 End of chemo in mantle is here ? ENRICH trial (Lancet 2025) 👥 397 untreated MCL (≥60 yrs) 💊 Ibrutinib + Rituximab (IR) vs 💉Immunochemotherapy (R-CHOP / R-Benda) 📊 Primary endpoint: PFS • IR > Chemo — HR 0.69 (0.52–0.90), p = 0.0034 • 🔹 vs R-CHOP HR 0.37